The Kelun Department welcomes a new coach born in the 1980s, and the 18.5 billion "infusion king" helps his son "move to the top"

Radar Finance

2026.11.22 09:02

· From Jiangsu

Full text 4611 words

Text | Radar Finance, author | Zhou Hui, editor | Meng Shuai

After 30 years in charge of Cologne, Liu Gexin, the "infusion king" with a net worth of 18.5 billion yuan, officially handed over the reins to his son Liu Sichuan.

On November 18, the A-share listed company Kelun Pharmaceutical issued an announcement stating that its founder Liu Gexin had resigned as chairman. After his resignation, he will continue to perform his duties as a director of the company and chairman of the strategy committee of the board of directors, and will continue to serve as chairman or director of some of the company's subsidiaries.

On the same day, Kelun Botai, a Hong Kong-listed subsidiary of Kelun Pharmaceutical Holdings, also disclosed that Liu Gexin had also resigned as chairman of the company's board of directors and continued to serve as the company's non-executive director.

The new coach who took over the No. 1 position of the two listed companies is Liu Sichuan, the son of Liu Gexin. Judging from his resume, Liu Sichuan, who was born in 1984, has been working in the Kelun system for nearly 20 years and has been involved in multiple systems such as finance, production, R&D, marketing, and capital operations.

However, this new coach born in the 1980s still faces many challenges. In the first three quarters of this year, Kelun Pharmaceutical achieved revenue of 13.113 billion yuan, a year-on-year decrease of 1.24%; it recorded net profit attributable to the parent company of 1.467 billion yuan, a year-on-year increase of 22.18%.

However, the growth of Kelun Pharmaceutical's net profit attributable to the parent company relies heavily on the settlement money Kelun Botai received previously. After deducting non-recurring gains and losses, the company's net profit attributable to the parent company in the first three quarters will decline by 7.48% year-on-year.

It is worth mentioning that in the first half of this year, Kelun Botai, which is responsible for the transformation of Kelun Pharmaceutical's innovative drugs, handed over a financial report with both revenue and net profit increasing.

In the first half of this year, Kelun Botai achieved revenue of 978 million yuan, a year-on-year increase of 2.93%; it recorded a net profit attributable to the parent company of 388 million yuan, turning a loss into a profit year-on-year.

The "Infusion King" gives way to the young marshal born in the 1980s

On November 18, Kelun Pharmaceutical issued an announcement stating that in order to better support the company's sustainable development, Chairman Liu Gexin recently submitted a resignation report to the board of directors and applied to resign as chairman of the company.

Kelun Pharmaceutical stated that after resigning as chairman, Liu Gexin will continue to perform his duties as a director of the company and chairman of the strategy committee of the board of directors, and will continue to serve as chairman or director of some of the company's subsidiaries.

As the founder of the company, 75-year-old Liu Gexin has led Kelun to gradually grow from a start-up company into a highly specialized innovative pharmaceutical group covering large-scale infusion, antibiotic intermediates, innovative drugs and general health industries over 30 years.

Set the timeline back to 1996. At that time, investment in the pharmaceutical industry gradually opened its door to private capital. Liu Gengxin took advantage of the opportunities of the times, resigned from his high-paying job, and founded Sichuan Kelun Pharmaceutical Factory, the predecessor of Kelun Pharmaceutical.

Under the leadership of Liu Gexin, Kelun Pharmaceutical subsequently relied on infusion products to gain a foothold in the market. Since then, the company has continued to delve into the field of infusion.

From 2003 to 2010, Kelun Pharmaceutical successively acquired more than ten infusion companies, significantly increasing the company's production capacity and establishing its position as the domestic leader in infusion. In June 2010, Kelun Pharmaceutical successfully entered the A-share capital market.

In this announcement, Kelun Pharmaceutical stated that Liu Gexin has always adhered to the corporate purpose of "scientific truth and ethical goodness" and devoted all his efforts in industrial upgrading, environmental protection, R&D system construction and global layout, making irreplaceable and historic contributions to Kelun's high-quality development.

With the resignation of Liu Genxin, Kelun Pharmaceutical will welcome a young marshal born in the 1980s - Liu Sichuan. And Liu Sichuan also has a special identity, that is, the son of Liu Gexin.

Kelun Pharmaceutical disclosed in the aforementioned announcement that the company held the 17th meeting of the eighth board of directors on the same day, and the "Proposal on the Election of Chairman of the Company" was unanimously reviewed and approved. Director Liu Sichuan was elected as the company's new chairman, with a term starting from the date of review and approval by the board of directors until the expiration of the term of the eighth board of directors.

At the same time, according to the relevant provisions of the "Articles of Association", Chairman Liu Sichuan will become the company's legal representative and continue to serve as the company's general manager.

On the same day, Kelun Botai, a Hong Kong-listed subsidiary of Kelun Pharmaceutical Holdings, also issued an announcement stating that Liu Gexin had resigned as chairman of the board of directors and continued to serve as the company's non-executive director, while Liu Sichuan was elected as the new chairman of the board of directors.

Public information shows that Liu Sichuan was born in 1984, has a master's degree, and is a senior economist.

As of now, Liu Sichuan directly holds approximately 8.3463 million shares of Kelun Pharmaceutical, and indirectly holds 22.6506 million shares of the company through the "Tongyi Wutong No. 10, 13 and 20 Private Securities Investment Funds" managed by Shanghai Tongyi Investment Management Co., Ltd.

In 2007, Liu Sichuan officially joined Kelun Pharmaceutical as the assistant to the chairman; joined the company's board of directors in June 2009; served as deputy general manager in July 2012; and was promoted to general manager of the company in September 2015.

Judging from his career experience, Liu Sichuan has worked in the Kelun system for nearly 20 years and is involved in multiple systems such as finance, production, R&D, marketing, and capital operations.

Some analysts believe that Liu Sichuan's succession this time follows the "management-board-chairman" succession path of the second generation of Sichuan enterprises. Nowadays, the parent and subsidiary companies of the Kelun Group have changed managers simultaneously, which means that the strategic decision-makers have completed the transition from Liu Gexin to Liu Sichuan.

In the first three quarters, “increased profits but not revenue”, Kelun Pharmaceutical’s main infusion business is under pressure

As early as 2016, Liu Gexin publicly stated that he would complete the change of chairman of the company during the heyday of the company and when there is no external crisis. However, judging from the company's recent performance, Kelun Pharmaceutical is facing certain pressure.

Looking back on 2025, Kelun Pharmaceutical achieved revenue of 18.513 billion yuan, a year-on-year decrease of 15.13%; it recorded a net profit attributable to the parent company of 1.702 billion yuan, a year-on-year decrease of more than 40%.

In the first three quarters of this year, Kelun Pharmaceutical handed over a performance answer sheet of "increasing profits without increasing revenue": During the reporting period, the company's revenue fell 1.24% year-on-year to 13.113 billion yuan; the net profit attributable to the parent company was approximately 1.467 billion yuan, an increase of 22.18% over the same period last year.

However, the company's non-net profit during the same period fell by 7.48% year-on-year to 1.061 billion yuan. This means that Kelun Pharmaceutical’s net profit growth in the first three quarters was mainly due to the contribution of non-recurring gains and losses.

The financial report shows that in the first three quarters of this year, Kelun Pharmaceutical's non-operating income was approximately 711 million yuan, a surge of 15223.71% compared with the same period last year. This increase in income was mainly due to the settlement funds received during the reporting period.

In June previously, Kelun Pharmaceutical disclosed through an announcement that the company's holding subsidiary Kelunbotai received 603 million yuan in revenue that Suzhou Yilian Biopharmaceutical Co., Ltd. (referred to as "Yilian Biopharmaceutical") should share with Kelunbotai regarding the external authorization of YL201.

According to the announcement, this revenue stems from the settlement agreement entered into between Kelunbotai and Yilian Biopharmaceuticals on December 16 last year - Yilian Biopharmaceuticals should pay for YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL) in its pipeline 3) A certain proportion of the revenue generated through external licensing of YL221 (EGFR) and YL222 (PD-L1) before the effective date of the settlement, as well as the revenue and net profit (if applicable) generated through external licensing and future sales after the effective date of the settlement, will be shared with Kelun Botai.

Kelun Pharmaceutical stated that from the beginning of the year to the date of the announcement, Kelun Botai received a total settlement of approximately 703 million yuan (including the aforementioned 603 million yuan). Calculated based on the company’s equity ratio of Kelun Botai, it accounted for 23.3% of the company’s audited net profit attributable to the parent company in 2025.

Back to the company's main business, in terms of products, Kelun Pharmaceutical's revenue mainly consists of three major segments: infusion, non-infusion and research and development projects.

Flush iFinD data shows that for a long time, infusion products have occupied Kelun Pharmaceutical’s largest source of revenue all year round. However, after 2024, this sector’s revenue share will be overtaken by the non-infusion sector.

In the first half of this year, Kelun Pharmaceutical's infusion business achieved sales of 1.929 billion bottles/bags, a year-on-year decrease of 0.94%; sales revenue was approximately 3.559 billion yuan, a year-on-year decrease of 5.08%.

Kelun Pharmaceutical stated that during the reporting period, Sichuan's inter-provincial alliance for large-volume injections such as sodium chloride was implemented with volume-linked procurement, the company moderately reduced prices and actively renewed bids during the renewal of 1-8 batches of national centralized procurement, and continued to favor sales policies for some highly competitive therapeutic products, which had a certain impact on sales revenue in the first half of this year.

During the same period, Kelun Pharmaceutical's non-infusion drugs (excluding innovative drugs) achieved sales revenue of 1.699 billion yuan, a year-on-year increase of 3.26%; R&D projects contributed revenue of 320 million yuan, a year-on-year decrease of nearly 50%.

In addition, affected by factors such as reduced overseas licensing revenue, Kelun Pharmaceutical's overseas revenue has also been under pressure. Revenue in the first half of the year was approximately 771 million yuan, a year-on-year decrease of 31.81%.

In the first three quarters of this year, Kelun Pharmaceutical's gross sales profit margin was 47.39%, down about 0.5 percentage points from the same period last year.

After many years of deploying innovative drugs, Kelunbotai successfully turned around losses in the first half of the year

While parent company Kelun Pharmaceutical's performance is under pressure, its innovative pharmaceutical subsidiary Kelun Botai has delivered a relatively eye-catching semi-annual report.

Information from Tianyancha shows that Sichuan Kelunbotai Biopharmaceutical Co., Ltd. ("Kelonbotai") was registered and established in 2016, and was later listed on the main board of the Hong Kong Stock Exchange in July 2023.

It is understood that Colombote is a biopharmaceutical company dedicated to the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology, metabolism and other therapeutic fields.

Citing Frost & Sullivan data, Colombote said it is the first Chinese company to license an internally discovered and developed ADC drug candidate to a top ten biopharmaceutical multinational company.

As of the end of the first half of the year, Kelun Botai's business has covered 30 provinces, more than 300 prefecture-level cities and more than 2,000 hospitals; its commercialization team has exceeded 800 people, almost doubling compared with the same period last year.

In the first half of this year, Kelun Botai achieved revenue of 978 million yuan, a year-on-year increase of 2.93%; it recorded a net profit attributable to the parent company of 388 million yuan, turning a loss into a profit year-on-year; its gross profit margin was 75.3%, a year-on-year increase of approximately 5.9 percentage points.

The financial report shows that Kelunbotai's revenue is mainly composed of three major segments: revenue from licensing and cooperation agreements, revenue from R&D services, and revenue from drug sales.

In the first half of this year, the company's revenue from drug sales was approximately 657 million yuan, a year-on-year increase of 112.12%. This sector became the main engine of the company's current performance growth.

During the same period, the company's revenue from licensing and cooperation agreements and revenue from R&D services were 315 million yuan and 6.781 million yuan respectively, a year-on-year decrease of 49.92% and 46.5%, which dragged down the company's revenue performance to a certain extent.

Radar Finance noted that as one of the pioneers in developing ADCs, Kelun Botai has continued to increase investment in research and development in recent years.

Flush iFinD data shows that from 2021 to 2025, the company's R&D expenses were 728 million yuan, 846 million yuan, 1.031 billion yuan, 1.206 billion yuan and 1.32 billion yuan respectively, accounting for 2251.31%, 105.23%, 66.92%, 62.4% and 64.13% of the current revenue.

In the first half of this year, Kelun Botai’s research and development expenses were approximately 768 million yuan, a year-on-year increase of 25.66%, accounting for 78.54% of operating income.

With continuous “burning money” investment in R&D, Kelun Botai has achieved fruitful results.

According to the official website, the company has obtained marketing authorization for Sac-TMT (Cateral®), tagolizumab (Cateral®), cetuximab N01 (Cateral®) and Bodutrastuzumab (Cateral®), and has begun the commercialization process.

Among them, Sac-TMT (Jitaly®) and Bodutrastuzumab (Sac-TMT®) are the two core ADC drug products of Kelunbotai.

It is reported that Sac-TMT (Jitaile®) is China's first domestic TROP2 ADC approved for marketing and China's first domestic ADC fully approved for marketing. Kelun Botai owns the independent intellectual property rights of this product.

Trastuzumab (Sertelex®) is a differentiated HER2 ADC for the treatment of advanced HER2+ solid tumors. It is positioned to target a variety of cancer indications with high prevalence and huge medical needs, including BC (breast cancer).

In addition, Colombote also disclosed in its semi-annual report that it is developing more than 30 pipeline assets, including core products that have been approved by the State Food and Drug Administration for marketing in China, as well as tagolimab and cetuximab N01.

However, the huge investment in research and development has also caused Kelun Botai to be trapped in a quagmire of losses for a long time. Flush iFinD data shows that from 2021 to 2025, the company suffered losses of 823 million yuan, 548 million yuan, 522 million yuan, 267 million yuan and 382 million yuan respectively, with the cumulative loss amounting to 2.542 billion yuan.

Some analysts pointed out that the aforementioned 703 million yuan settlement of Yilian Biotechnology was the key to Kelun Botai's performance in the first half of the year turning losses into profits. The company's continued profitability remains to be further observed.

It is worth mentioning that in addition to Kelun Pharmaceutical and Kelun Botai, Liu Gexin and Liu Sichuan and his son also control another A-share listed company, Chuan Ning Biologics, of which Liu Gexin is still the chairman.

As of the close of trading on November 20, the stock prices of Kelun Pharmaceutical, Twinings Biotechnology, and Kelun Botai were respectively at 40.71 yuan/share, 7.25 yuan/share, and 398.4 Hong Kong dollars/share; their market values ​​were 64.761 billion yuan, 16.184 billion yuan, and 95.227 billion Hong Kong dollars respectively.

In the "2026 Hurun Rich List" released at the end of October, Liu Gexin's personal wealth was approximately 18.5 billion yuan, an increase of 500 million yuan from the previous year.

Respect for the original work, if you are qualified, you should be appreciated.

According to the real-name requirement of the Cybersecurity Law, please bind your mobile phone number before posting a comment.

Express

09:09

Trump plans to join forces with Democrats to cap credit card interest rates at 10%

09:05

Iran’s President: The ongoing economic war is “far more difficult” than a military conflict

2026-11-21 22:48

Qatari delegation arrives in Iran for two-hour consultation

2026-11-21 22:31

AIIB to set up office in Hong Kong

2026-11-21 21:12

China has more than 27,000 “5G+industrial Internet” projects

Zelensky meets with British Defense Secretary to discuss building Ukrainian air defense capabilities

2026-11-21 20:12

18 quick facts about News Network on November 21

2026-11-21 19:21

Iran says oil tanker caught fire in waters east of Strait of Hormuz

2026-11-21 18:51

Trump criticizes the Fed for high interest rates, putting the Fed chairman in a dilemma

2026-11-21 18:50

An earthquake of around 5.7 magnitude occurred near Delingha City, Haixi Prefecture, Qinghai Province

2026-11-21 18:31

Many brands announced: lowering gold jewelry prices per gram

2026-11-21 18:13

Two oil tankers were attacked one after another as they sailed out of the Strait of Hormuz

2026-11-21 17:55

A 7.2-magnitude earthquake occurred in the sea near Maluku Province, Indonesia

2026-11-21 17:40

Chongqing released a list of 86 low-altitude industrial development opportunities, with a total investment of approximately 28.9 billion yuan

2026-11-21 16:53

Li Qiang held talks with Singaporean Prime Minister Lawrence Wong

National Data Administration: Actively expand the application scenarios of word unit services, and improve standards and specifications for word unit measurement and billing, quality assessment, etc.

2026-11-21 16:43

The Shenzhou 24 mission completed its last region-wide joint training, and the launch site made preparations for launch

2026-11-21 16:25

Iranian Foreign Minister: Iran is still willing to resolve disputes with the United States through diplomatic channels

2026-11-21 16:02

South-to-North Water Diversion Project "Tianhe" large model completed upgrade

2026-11-21 15:46

Iranian Foreign Minister: Enriched uranium will not be shipped out of Iran

Scan to download App